ArticleCurrent microbiology2026
Eugenol Activity Against Escherichia coli and Staphylococcus aureus: Biofilm Disruption and Additive Interactions with Antibiotics.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multidrug-resistant bacteria and their ability to form biofilms represent significant challenges in infection control. This study evaluated the antibacterial and antibiofilm activities of eugenol (Eug) against Escherichia coli and Staphylococcus aureus from food and clinical sources. Antibacterial activity was assessed using disk diffusion, broth microdilution (MIC/MBC), and bacterial growth kinetics. Antibiofilm activity was measured by crystal violet staining, CFU enumeration, and scanning electron microscopy (SEM). Checkerboard assays evaluated the combinatorial effect of Eug with ciprofloxacin and oxacillin. Eug exhibited inhibition zones of 13-22 mm and MIC/MBC values of 1000-2000 µg/mL. Subinhibitory concentrations significantly delayed bacterial growth. Biofilm biomass was reduced by up to 90% in E. coli and 80% in S. aureus, with SEM confirming structural alterations. Checkerboard assays revealed additive interactions with antibiotics. These findings provide additional evidence of Eug's antibacterial properties and support further investigation into its combinatorial effects with antibiotics against biofilm-associated challenges.
Indexed as
Identifiers
42909636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.